Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To compare the efficacy of mirabegron and doxazosin in alleviating ureteral stent-related symptoms and sexual dysfunction.
Method: This study included 107 patients who provided informed consent and underwent transurethral ureteral lithotripsy with ureteral stent placement between January 2023 and December 2023. Patients were randomized into two groups receiving either mirabegron (50 mg/day) or doxazosin (4 mg/day). The Ureteral Stent Symptom Questionnaire (USSQ) scores and adverse drug reactions were recorded at baseline (ureteral stent placement), 2 weeks (ureteral stent removal), and 4 weeks (2 weeks after stent removal). The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2500095161).
Results: At 2 weeks, the mirabegron group showed a greater improvement in pain during intercourse compared to the doxazosin group (0.379 ± 0.186; p = 0.043). This improvement persisted at 4 weeks (0.363 ± 0.186). No significant differences were observed in sexual satisfaction scores between the groups at either time point (2 weeks: 0.175 ± 0.186, p = 0.350; 4 weeks: 0.157 ± 0.186, p = 0.401). Subgroup analysis revealed that mirabegron provided greater relief of pain during intercourse in women compared to doxazosin (OR = 14.40, 95% CI 1.53-135.51, p = 0.020). Additionally, women in the doxazosin group reported significantly lower sexual satisfaction compared to the mirabegron group (OR = 42.00, 95% CI 2.41-825.71, p = 0.014).
Conclusions: Mirabegron and doxazosin demonstrated similar efficacy in relieving ureteral stent-related symptoms. However, mirabegron offered a clear advantage in improving female sexual function, particularly regarding pain during intercourse and overall satisfaction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075346 | PMC |
| http://dx.doi.org/10.1007/s00345-025-05663-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of remote follow-up under an intelligent medical collaboration model on health promotion and clinical outcomes in patients with urinary calculi.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Outpatient, Third Xiangya Hospital, Central South University, Changsha 410013.
Objectives: Urinary calculi are characterized by a high recurrence rate, and patients' adherence to self-management after discharge directly affects health outcomes. Traditional offline follow-up models often face problems such as poor compliance and uneven allocation of medical resources, making it difficult to meet individualized health management needs. Remote follow-up provides a novel solution to optimize long-term management, improve health literacy, and enhance clinical outcomes.
View Article and Find Full Text PDFCase report: Duplicate renal ureteral malformation with renal tumor, ureteral tumor, renal rupture, calculi and infection.
Int J Surg Case Rep
September 2025
Department of Urology, Shandong Provincial Third Hospital, Shandong University, Jinan, 250012, China; Shandong Stone Disease Prevention and Treatment Center, Jinan, 250012, China. Electronic address:
Introduction: The Multiple primary malignant tumors (MPMT) refers to the occurrence of two primary malignant tumors in the same organ or organs in the same patient at the same time. However, MPMT is rare in the urinary system. Congenital urinary tract anomalies (e.
View Article and Find Full Text PDFIs it prime time for stent-less robotic radical cystectomy? A scoping review.
J Robot Surg
September 2025
Consultant Urological Surgeon, Royal Surrey NHS Foundation Trust, Guildford, UK.
The gold standard treatment for muscle-invasive bladder cancer (MIBC) still is radical cystectomy. Thanks to better peri-operative results than open surgery, robotic-assisted radical cystectomy (RARC) has become somewhat well-known. Though they are linked with problems like infection, pain, and higher healthcare expenses, conventionally ureteral stents are used during urinary diversion to minimize anastomotic leaks and strictures.
View Article and Find Full Text PDF[Symptoms and treatment of benign prostatic hyperplasia patients with upper urinary tract calculi after ureteral stent implantation].
Zhonghua Nan Ke Xue
July 2025
Department of Urology, Baoji People's Hospital Affiliated to Yan'an University, Baoji, Shaanxi 721000, China.
Objective： To analyze the symptoms, diagnosis and treatment of upper urinary tract calculi patients combined with mild and moderate benign prostatic hyperplasia (BPH) after ureteral stent implantation. Methods： One hundred and six BPH patients who were hospitalized for upper urinary tract calculi and had ureteral stents retained from January 2019 to December 2022 were selected and divided into 2 weeks group and 4 weeks group according to the time of removal of ureteral stents after surgery. Their general clinical data were analyzed and compared.
View Article and Find Full Text PDFAssociations between ureteral stent indwelling time, patient characteristics, and stent pain from an international prospective registry.
Can J Urol
August 2025
Department of Urology, Mayo Clinic Phoenix, Boulevard Phoenix, AZ 85054, USA.
Objectives: Previous studies have shown conflicting results concerning the optimal duration of ureteral stenting after endourologic treatment of stone disease, its effect on patient comfort, and the necessity for emergent, unscheduled care. This study assessed the impact of stent duration, sex, and other patient-associated factors on reported pain scores using a large, international prospective registry.
Methods: A prospective observational patient registry on ureteral stents from 10 institutions in 4 countries (United States, Canada, France, and Japan) from 2020-2023 was assessed.